Key facts
- GlycoEra’s last known valuation is $70.8M (Jan 2024).
- It has raised $193.6M; the latest was Later Stage VC ($130.0M) in May 2025.
- Notable investors include Novo Holdings, Qatar Investment Authority, Catalio Capital Management, Sofinnova Partners, Bristol-Myers Squibb — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for GlycoEra
- ·The full record, as it builds
Funding rounds
No funding rounds for GlycoEra are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About GlycoEra
Operator of a biotech company intended for medical needs in inflammatory, autoimmune, and immune-oncology. The company offers a proprietary platform that develops therapeutics with customized and homogenous human glycans assembled onto glycoproteins in a site-specific manner, enabling healthcare companies to understand the role of glycans in human health and diseases.
- Sector
- Healthcare
- HQ
- Wädenswil, Switzerland
- Founded
- 2020
- Employees
- 35
- Website
- glycoera.com/
- Ownership
- Privately Held (backing)
GlycoEra doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in GlycoEra shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on GlycoEra in its N-PORT filings yet. We sweep new filings monthly.